Skip to main content

Advertisement

Table 1 Patient characteristics

From: Phase I/II study of first-line irinotecan combined with 5-fluorouracil and folinic acid Mayo Clinic schedule in patients with advanced colorectal cancer

Characteristics* Phase I (n = 14) Phase II (n = 49)
Eligible 14 (100%) 45 (92%)
Evaluable 11 (79%) 36 (73%)
Median age (range) years 59.0 (30.0–69.0) 63.0 (37.0–71.0)
Sex
   Male 7 (50%) 33 (67%)
   Female 7 (50%) 16 (33%)
WHO performance status
   0 4 (29%) 14 (29%)
   1 10 (71%) 31 (63%)
   2 0 4 (8%)
Primary tumour site
   Colon 9 (64%) 17 (35%)
   Rectum 4 (29%) 22 (45%)
   Colon rectosigmoid 1 (7%) 10 (20%)
Organ involved
   Median number 2 (1–4) 2 (1–4)
   Liver 10 (71%) 42 (86%)
   Lung 6 (43%) 17 (35%)
   Lymph node 1 (7%) 10 (20%)
   Other soft tissue 0 11 (22%)
   Abdominal cavity 2 (14%) 3 (6%)
   Peritoneum 1 (7%) 0
   Bone 1 (7%) 0
   Skin 0 1 (2%)
   Other 2 (14%) 5 (10%)
Prior therapy
   Surgery 12 (86%) 42 (86%)
   Radiotherapy 3 (21%) 14 (29%)
   Adjuvant chemotherapy 4 (29%) 12 (24%)
   Surgery + radiotherapy 3 (21%) 12 (24%)
   Surgery + chemotherapy 4 (29%) 12 (24%)
   Radiotherapy + chemotherapy 2 (14%) 7 (14%)
   Surgery + radiotherapy + chemotherapy 2 (14%) 7 (14%)
  1. *N (%) unless otherwise stated. WHO = World Health Organization.